References
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work GroupKDIGO clinical practice guideline for glomerulonephritisKidney Int Suppl201222139274
- AletahaDNeogiTSilmanAJ2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
- BykerkVPSchoelsMMTreatment strategies for early rheumatoid arthritis (1988/2500)Curr Opin Rheumatol201325337538323508130
- Umicevic MirkovMCoenenMJPharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicinePharmacogenomics201314442544423438889
- BalcerLJClinical practice. Optic neuritisN Engl J Med2006354121273128016554529
- Optic Neuritis Treatment Trial (ONTT)2015 Available from: http://www.nei.nih.gov/neitrials/static/study47.aspAccessed February 5, 2015
- MurphyMAClinical update on optic neuritis and multiple sclerosisMed Health R I2008912575918372861
- BrusaferriFCandeliseLSteroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trialsJ Neurol2000247643544210929272
- CattranDCAppelGBGlassockRJFervenzaFCFormanJPTreatment of primary focal segmental glomerulosclerosis2015 Available from: http://www.uptodate.com/contents/treatment-of-primary-focal-segmental-glomerulosclerosis?source=search_result&search=treatment+of+primary+focal+segmental+glomeruloscleros&selectedTitle=1~150Accessed February 5, 2015
- GongRThe renaissance of corticotropin therapy in proteinuric nephropathiesNat Rev Nephrol20128212212822143333
- CataniaAGattiSColomboGLiptonJMTargeting melanocortin receptors as a novel strategy to control inflammationPharmacol Rev200456112915001661
- GettingSJTargeting melanocortin receptors as potential novel therapeuticsPharmacol Ther2006111111516488018
- GettingSJKanevaMBhadresaYMelanocortin peptide therapy for the treatment of arthritic pathologiesSci World J2009913941414
- PatelHBBombardieriMSampaioALAnti-inflammatory and antiosteoclastogenesis properties of endogenous melanocortin receptor type 3 in experimental arthritisFASEB J201024124835484320702773
- BombackASCanettaPABeckLHJrAyalonRRadhakrishnanJAppelGBTreatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trialAm J Nephrol2012361586722722778
- HoganJBombackASMehtaKTreatment of idiopathic FSGS with adrenocorticotropic hormone gelClin J Am Soc Nephrol20138122072208124009220
- BombackASTumlinJABaranskiJTreatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gelDrug Des Devel Ther20115147153
- MadanAMilwardASTeehanGSMijovic-DasSKhastgirATreatment of nephrotic syndrome with Acthar® Gel: a retrospective case seriesPresented at: The National Kidney Foundation 2014 Spring Clinical MeetingsApril 22–26, 2014Las Vegas, NV
- Questcor Pharmaceuticals, Inc. H.P. Acthar® Gel (repository corticotropin injection), 80 U/mLImportant Safety Information2015 Available from: http://www.acthar.com/important-safety-information.htmlAccessed February 5, 2015
- GongRLeveraging melanocortin pathways to treat glomerular diseasesAdv Chronic Kidney Dis201421213415124602463
- HumphreysMHCardiovascular and renal actions of melanocyte-stimulating hormone peptidesCurr Opin Nephrol Hypertens2007161323817143069
- GreenfieldJRMillerJWKeoghJMModulation of blood pressure by central melanocortinergic pathwaysN Engl J Med20093601445219092146
- HallstromAPVerterJFriedmanLRandomizing respondersControl Clin Trials19911244865031657526
- D’AgatiVDPodocyte injury in focal segmental glomerulosclerosis: lessons from animal models (a play in five acts)Kidney Int200873439940617989648
- GongRDworkinLDACTH (Acthar Gel) prevents proteinuria and renal injury in the remnant kidney: evidence for direct podocyte protection [abstract]J Am Soc Nephrol201021Suppl548A20299354
- LindskogAEbeforsKJohanssonMEMelanocortin 1 receptor agonists reduce proteinuriaJ Am Soc Nephrol20102181290129820507942